Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:56 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22012

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Interventions: MACI, microfracture; Biological · Procedure
Lead sponsor: Vericel Corporation; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 15
States / cities: Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 10 more

Conditions: Alzheimer's Disease
Interventions: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: Left-sided Colorectal Cancer
Interventions: Petosemtamab, Cetuximab, FOLFIRI, mFOLFOX6; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Hot Springs, Arkansas • Los Angeles, California • Savannah, Georgia + 6 more

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan; Other · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 108
States / cities: Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: JNJ-90301900, Cisplatin, Intensity Modulated Radiation Therapy (IMRT), Carboplatin, Paclitaxel; Drug · Radiation
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 7 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Midazolam, Oral Placebo, Intranasal Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 12
States / cities: Birmingham, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more

Conditions: Advanced-stage Solid Tumors
Interventions: JNJ-89862175; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Orlando, Florida • Boston, Massachusetts • Irving, Texas

Conditions: Speech Sound Disorder
Interventions: Visual-acoustic biofeedback; Behavioral
Lead sponsor: New York University; Other
Eligibility: 9 Years to 17 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Bloomfield, New Jersey • New York, New York • Syracuse, New York

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Interventions: Pirtobrutinib, Venetoclax, Obinutuzumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Orthopaedic Fractures, Socioeconomic Factors
Interventions: Social Work support; Other
Lead sponsor: Sheila Sprague; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 2
States / cities: Oakland, California • Chicago, Illinois

Recruiting clinical trials

Filter and sort this status page

Live official records

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Visual-acoustic Intervention With Service Delivery In-person and Via Telepractice Trial

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Trial of Social Work Services in Fracture Clinic Setting

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse